



PRODUCT SPECIFICATIONS

UROLOGY & UROGYNECOLOGY

Optilume® Urethral Drug Coated Balloon

Intended Use

Optilume[®] Urethral Drug Coated Balloon is intended for the treatment of strictures in the anterior urethra in adult males.

Description

The Optilume® Urethral Drug Coated Balloon is a 0.038" (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered atraumatic tip. Balloon diameters of 6 mm-10 mm (18 Fr-30 Fr) are flexible cystoscope compatible. The Optilume® DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon.



Indications for Use

The Optilume® Urethral Drug Coated Balloon is used to treat patients with obstructive urinary symptoms associated with anterior urethral stricture. It is designed to be used in adult males for anterior urethral strictures of \leq 3 cm in length.


Storage

The Optilume® Urethral Drug Coated Balloon should be stored at room temperature in a dry location in its original packaging. The device should be used prior to the "Use by" date on the packaging.

Contraindications

The Optilume® Urethral Drug Coated Balloon is contraindicated for use in:

- Patients with known hypersensitivity to paclitaxel or structurally related compounds
- Patients with urologic implants such as penile implants and artificial urinary sphincters



PRODUCT SPECIFICATIONS

PRODUCT USAGE					
System Compatibility	18 Fr-30 Fr: Rigid and Flexible Cystoscope Compatible Minimum Working Channel Size: 2.1mm (6 Fr)				
Procedure Type	Male Anterior Urethral Stricture Dilation				
CERTIFICATION					
ARTG Identifier	385332				
ARTG Start Date	09Mar22				
Product Category	Medical Device Included Class III				
GMDN	62313 Urethral dilatation catheter, drug-eluting				
TECHNICAL DATA					
Balloon Lengths	3 and 5 cm				
Balloon Diameters	18 Fr, 24 Fr, 30 Fr				
Rated Burst Pressure	18 Fr and 24 Fr: 12 atm; 30 Fr: 10 atm				
Crossing Profile	18 Fr, 24 Fr, and 30 Fr: 0.083" (6.3 Fr)				
Catheter Design	Over-the-Wire (OTW)				
Guidewire Compatibility	0.038" Maximum				
Catheter Length	75 cm				

TECHNICAL DATA cont.				
Balloon Fold Configuration	5-fold			
Balloon Markers	Platinum-Iridium			
Drug	Paclitaxel			
Drug Dose	3.5 μg/mm²			
Drug Coated Area	Balloon Body (Shown by cross-hatch in image on front)			
MATERIAL				
Catheter Principal Elements	Nylon 12, Pebax, Polycarbonate, and Platinum-Iridium			
STERILIZATION				
Single Use/Disposable	Yes			
Sterile	Ethylene Oxide			
Place of Sterilization	Steris Applied Sterilization Technologies, Coon Rapids, Minnesota			
Shelf Life	12 Months			
PACKAGING				
Package Material	Tyvek® and PET/LDPE/Nylon composite			
Quantity Per Box	One (1)			

Product Number	Description	Diameter	Length	Rated Burst Pressure (RBP)
1110-06030D	Optilume® Urethral Drug Coated Balloon & Inflation Device	18 Fr	3 cm	12 atm
1110-06050D	Optilume® Urethral Drug Coated Balloon & Inflation Device	18 Fr	5 cm	12 atm
1110-08030D	Optilume® Urethral Drug Coated Balloon & Inflation Device	24 Fr	3 cm	12 atm
1110-08050D	Optilume® Urethral Drug Coated Balloon & Inflation Device	24 Fr	5 cm	12 atm
1110-10030D	Optilume® Urethral Drug Coated Balloon & Inflation Device	30 Fr	3 cm	10 atm
1110-10050D	Optilume® Urethral Drug Coated Balloon & Inflation Device	30 Fr	5 cm	10 atm
96313	Atrion QL4015 Disposable Inflation Device	N/A	N/A	N/A

Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. The Optilume® DCB is indicated for use in patients with obstructive urinary symptoms associated with anterior urethral stricture. It is designed to be used in adult males for anterior urethral strictures of £3cm in length. The Optilume® DCB is contraindicated for patients with known hypersensitivity to paclitaxel or structurally related compounds and patients with urologic implants such as penile implants or artificial urinary sphincters. Paclitaxel may be present in semen after treatment with the Optilume® DCB. The risks associated with paclitaxel in semen and the impact on sperm and spermatogenesis are unknown. Men should abstain or use a condom for 30 days and men with partners of child-bearing potential should use highly effective contraceptive and avoid fathering children for 6 months after treatment. Monitor for signs of anaphylaxis or hypersensitivity to paclitaxel. Potential risks can include, but are not limited to, the following: blood in the urine (hematuria), painful urination (dysuria), urinary tract infection (UTI), and urinary retention.



Optilume® urethral drug coated balloon

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE.

©2024 Laborie. All rights reserved.

For further information, please visit us at www.optilume.com

Manufactured by Urotronic, Inc.



AUSTRALIA

T +07 3862 2000 F +07 3862 2077 E enquiries@laborie.com.au

W aus.laborie.com

